Vertex Pharmaceuticals Inc VRTX:NASDAQ

Last Price$234.67Cboe Real-Time Last Sale as of 1:01PM ET 1/21/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.16(0.49%)
Bid (Size)$234.58 (5)
Ask (Size)$234.79 (100)
Day Low / High$233.88 - 237.20
Volume491.5 K

View Biotechnology IndustryPeer Comparison as of 01/21/2020


Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $234.67
Change: -1.16 (0.49%)
Volume: 491.5 K
1:01PM ET 1/21/2020

Biogen Inc ( NASDAQ )

Price: $284.26
Change: -1.24 (0.43%)
Volume: 1.2 M
1:01PM ET 1/21/2020

Illumina Inc ( NASDAQ )

Price: $329.14
Change: +4.42 (1.36%)
Volume: 562.3 K
1:00PM ET 1/21/2020

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $367.87
Change: -18.07 (4.68%)
Volume: 636.6 K
1:01PM ET 1/21/2020

Read more news Recent News

Stocks End Higher After Trump Says Iran "Standing Down" After Attacks on Iraqi Bases
4:38PM ET 1/08/2020 MT Newswires

Stocks ended higher Wednesday as tensions between the US and Iran appear to have eased after the Islamic Republic's rocket attacks overnight on military...

--Analyst Actions: Citigroup Hikes Price Target for Vertex Pharmaceuticals to $265 From $225, Maintains Buy Rating
12:04PM ET 1/08/2020 MT Newswires

Price: 231.58, Change: +7.79, Percent Change: +3.48 ...

--Analyst Actions: Oppenheimer Raises Price Target on Vertex Pharmaceuticals to $265 From $230, Keeps Outperform Rating
10:07AM ET 1/08/2020 MT Newswires

Price: 228.76, Change: +4.97, Percent Change: +2.22 ...

Stocks End Higher Despite Rising Tensions in Middle East Over Killing of Iranian General
4:29PM ET 1/06/2020 MT Newswires

Stocks ended higher on Monday, recovering from Friday's selloff over geopolitical concerns after the US military killed Iran's top military commander...

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Number of Employees2,500
Recent SEC Filing01/17/20204
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$235.84
Previous Close$235.83
52 Week Range$163.68 - 237.20
Market Capitalization$60.3 B
Shares Outstanding257.1 M
SectorHealth Technology
Next Earnings Announcement02/04/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings28.59
Earnings per Share$8.28
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin59.75%
Return on Equity44.02%

Analyst Ratings as of 12/16/2019

Consensus RecommendationConsensus Icon
Powered by Factset